⌕
Wave Life Sciences · WVE · Nasdaq
Tenet 54 · Mixed
Compare
$2.87−8.31%At closeTenet 54 · Mixed
$2.87−0.26 (−8.31%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Wave Life Sciences (WVE) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 13, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026

INLIGHT Phase 1 data continue to support WVE-007's novel mechanism of action to improve body composition by inducing fat loss without muscle loss, and support a once- or twice-yearly dosing regimen…

● GlobeNewsWireNov 11, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London

CAMBRIDGE, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, toda…

● Seeking AlphaNov 10, 2026 · 13:55 ET
Wave Life Sciences: Reversing Stock Losses Tricky Despite Near-Term AATD Readout

Wave Life Sciences, Inc. remains a 'Hold,' as I see limited near-term upside amid competitive obesity and AATD markets. WVE-007's modest ~1% weight loss at six months lags GLP-1 peers, though muscle preservation and dosi…

● The Motley FoolNov 8, 2026 · 18:00 ET
Wave: 3 Key Takeaways for Long-Term Investors

Wave aligned with the FDA on a single trial for WVE-006. Cash and marketable securities reached $431 million to fund operations into 2028.…

● Seeking AlphaNov 4, 2026 · 18:24 ET
Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript

Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript…

● MarketBeatNov 4, 2026 · 14:15 ET
WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program

WAVE Life Sciences NASDAQ: WVE used its 2026 Research Day to outline plans for WVE-008, an RNA-editing candidate being developed for liver disease associated with the PNPLA3 I148M genetic variant, while also providing up…

● Seeking AlphaOct 27, 2026 · 14:40 ET
Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript

Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript…

● MarketBeatOct 27, 2026 · 13:07 ET
WAVE Life Sciences Q3 Earnings Call Highlights

WAVE Life Sciences NASDAQ: WVE reported higher third-quarter revenue and a wider net loss as it increased investment in clinical programs spanning obesity, alpha-1 antitrypsin deficiency and liver disease.…

● Zacks Investment ResearchOct 27, 2026 · 09:41 ET
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.32 per share a year ago.…

● GlobeNewsWireOct 27, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers…

● MarketBeatOct 21, 2026 · 23:03 ET
WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

WAVE Life Sciences NASDAQ: WVE outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno emphasizing the company's chemistry platfo…

● GlobeNewsWireOct 20, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026

CAMBRIDGE, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will…

● GlobeNewsWireOct 19, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, anno…

● GlobeNewsWireOct 13, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, toda…

● Defense WorldOct 12, 2026 · 12:34 ET
WAVE Life Sciences (NASDAQ:WVE) Sets New 1-Year Low – Here’s Why

WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report)'s share price reached a new 52-week low during trading on Monday. The company traded as low as $3.37 and last traded at $3.3850, with a volume of 317,423 shares tra…

● Defense WorldOct 5, 2026 · 03:00 ET
Analyzing Tonix Pharmaceuticals (NASDAQ:TNXP) and WAVE Life Sciences (NASDAQ:WVE)

WAVE Life Sciences (NASDAQ: WVE - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies ba…

● Defense WorldOct 3, 2026 · 05:01 ET
WAVE Life Sciences (NASDAQ:WVE) Shares Climb 9.3% – Here’s What Happened

Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) rose 9.3% on Thursday. The company traded as high as $4.02 and last traded at $4.0440. 544,448 shares were traded during mid-day trading, a decline of 86%…

● Defense WorldOct 2, 2026 · 05:41 ET
WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up – Time to Buy?

Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $3.64, but opened at $3.79. WAVE Life Sciences shares last traded at $…

● GlobeNewsWireOct 1, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers…

● GlobeNewsWireSep 30, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development

Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing…

● Zacks Investment ResearchSep 28, 2026 · 12:01 ET
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.…

● GlobeNewsWireSep 23, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 a…

● GlobeNewsWireSep 22, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer

Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.…

● Defense WorldSep 22, 2026 · 06:15 ET
Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)

Septerna (NASDAQ: SEPN - Get Free Report) and WAVE Life Sciences (NASDAQ: WVE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just WVE · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.